en · de · es
selank-notes.peptides3081.com › Faq › Analytical Methods And Stability — Reference Sheet

Analytical Methods And Stability — Reference Sheet

By Editorial Desk · published 2025-12-19 · last reviewed 2026-01-23 · Faq

Everything below concerns Certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-01-23. Where a claim depends on a specific study, the study is described rather than over-claimed.

Analytical Methods and Stability

Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.

Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.

Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.

Storage, Analysis, and Regulatory Status

Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.

Selank at a glance

PropertyValueNotes
Identity confirmationReversed-phase HPLC retention time versus reference standardRetention depends on column, gradient, and ion-pairing agent
Mass confirmationElectrospray or MALDI mass spectrometryDoubly protonated ion near m/z 377 is consistent with about 752 Da
Typical purity specification95 percent or higher by chromatographic peak areaLower values suggest truncated or modified peptide species
Storage of lyophilized powder-20 °C, desiccated, protected from lightPowder tolerates long storage better than solution
Storage of solution2-8 °C for short periodsFreeze-thaw cycling promotes aggregation and surface adsorption

Selank Origin and Chemical Identity

Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.

The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.

Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.

Related pages on this site

Administration, Testing and Availability

Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.

Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.

Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.

Mechanism and Evidence Status

Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.

Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.

Notes from published material

=== Producing sulfuric acid from sulfur === A method of producing oleum sulphuris per campanam, or "oil of sulfur by the bell", was known by the 16th century: it involved burning sulfur under a glass bell in moist weather (or, later, under a moistened bell). However, it was very inefficient (according to Gesner, 5 pounds (2.3 kg) of sulfur converted into less than 1 ounce (0.03 kg) of acid), and the resulting product was contaminated by sulfurous acid (or rather, solution of sulfur dioxide) so most alchemists (including Isaac Newton) did not consider it equivalent to "oil of vitriol". In the 17th century, Johann Rudolf Glauber discovered that adding saltpeter (potassium nitrate, KNO3) and replacing moisture with steam significantly improves the output. As saltpeter decomposes, it oxidizes the sulfur to SO3, which combines with water to produce sulfuric acid. In 1736, Joshua Ward, a London pharmacist, used this method to begin the first large-scale production of sulfuric acid.

Most sexually reproducing organisms are diploid, with paired chromosomes, but doubling of their chromosome number may occur due to errors in cytokinesis. This can occur early in development to produce an autopolyploid or partly autopolyploid organism, or during normal processes of cellular differentiation to produce some cell types that are polyploid (endopolyploidy), or during gamete formation. An allopolyploid plant may result from a hybridisation event between two different species. Both autopolyploid and allopolyploid plants can often reproduce normally, but may be unable to cross-breed successfully with the parent population because there is a mismatch in chromosome numbers. These plants that are reproductively isolated from the parent species but live within the same geographical area, may be sufficiently successful to form a new species. Some otherwise sterile plant polyploids can still reproduce vegetatively or by seed apomixis, forming clonal populations of identical individuals. Durum wheat is a fertile tetraploid allopolyploid, while bread wheat is a fertile hexaploid. The commercial banana is an example of a sterile, seedless triploid hybrid. Common dandelion is a triploid that produces viable seeds by apomictic seed. As in other eukaryotes, the inheritance of endosymbiotic organelles like mitochondria and chloroplasts in plants is non-Mendelian. Chloroplasts are inherited through the male parent in gymnosperms but often through the female parent in flowering plants.

== Lawsuits == In February 2005, the Associated Press reported Nestlé lost a lawsuit and was ordered to pay US$15.6 million to Russell Christoff for using an image of him without his permission on their Taster's Choice label for approximately five years (1998–2003). The $15.6 million judgment was subsequently reversed in its entirety by the California Court of Appeal. On October 31, 2007, the California Supreme Court, with a vote of 6–0, granted review. On August 17, 2009, the court reversed the judgment (opinion S155242) and remanded the case to the trial court to consider whether the ad campaign covered a "single publication", which would have prevented Christoff from suing because the statute of limitations would have lapsed, or multiple publications.

planifolia seeds this way are Eulaema polychroma and Scaptotrigona subobscuripennis. Seeds being distributed by bees is a rare behavior and has only been documented in three species of tropical trees previously, the cadaghi (Corymbia torelliana), Coussapoa asperifolia subsp. magnifolia, and Zygia racemosa. Both rodents and marsupials are confirmed to consume fallen pods on the forest floor. Specific species observed eating the pods include Tome's spiny rat (Proechimys semispinosus) and the common opossum (Didelphis marsupialis). Further experiments by a team led by Dr. Adam Karremans showed that the seeds remained viable after being passed through the mammalian gut, but it did not increase or decrease germination significantly.

Sources: en.wikipedia.org

Further detail

bond Any persistent attraction between atoms, ions, or molecules that enables the formation of chemical compounds. Bonds are created as a result of a wide variety of electrochemical forces, whose strengths can vary considerably; they are broken when these forces are overcome by other forces. The types, strengths, and quantities of bonds holding together chemical substances dictate the structure and bulk properties of matter.

=== Intestinal colonization and sepsis === Enterohemorrhagic E. coli (EHEC) and enteropathogenic E. coli (EPEC) are pathogens that rely on OmpT to colonize in the intestine of their host. In response to the presence of E. coli in the gut, the host releases antimicrobial peptides as part of the innate immune response. Since OmpT can break down these antimicrobials and inactivate them, EHEC and EPEC can colonize within the colon or small intestine of the host and lead to serious diarrheal diseases. In the case of sepsis, the host activates the blood clotting system to deposit fibrin and limit the spread of bacteria throughout the blood. However, OmpT can inactivate the tissue factor pathway inhibitor (TFPI), counteracting the host's immune response, and further perpetuating the spread of extraintestinal E. coli infection.

An adult's trachea has an inner diameter of about 1.5 to 2 centimetres (1⁄2 to 3⁄4 in) and a length of about 10 to 11 cm (4 to 4+1⁄4 in), wider in males than females. The trachea begins at the lower edge of the cricoid cartilage of the larynx at the level of sixth cervical vertebra (C6) and ends at the carina, the point where the trachea branches into left and right main bronchi., at the level of the fourth thoracic vertebra (T4), although its position may change with breathing. The trachea is surrounded by 16–20 rings of hyaline cartilage; these 'rings' are 4 millimetres high in the adult, incomplete and C-shaped. Ligaments connect the rings. The trachealis muscle connects the ends of the incomplete rings and runs along the back wall of the trachea. Also adventitia, which is the outermost layer of connective tissue that surrounds the hyaline cartilage, contributes to the trachea's ability to bend and stretch with movement. Although trachea is a midline structure, it can be displaced normally to the right by the aortic arch.

Sources: en.wikipedia.org

Supporting material

Rarely, the inhibition of carbonic anhydrase may be strong enough to cause metabolic acidosis of clinical importance. The U.S. Food and Drug Administration (FDA) has notified prescribers that topiramate can cause acute myopia and secondary angle closure glaucoma in a small subset of people who take a lot of topiramate. The symptoms, which typically begin in the first month of use, include blurred vision and eye pain. Discontinuation of topiramate may halt the progression of the ocular damage and may reverse the visual impairment. Preliminary data suggests that, as with several other anti-epileptic drugs, topiramate carries an increased risk of congenital malformations. This might be particularly important for women who take topiramate to prevent migraine attacks. In March 2011, the FDA notified healthcare professionals and patients of an increased risk of development of cleft lip and/or cleft palate (oral clefts) in infants born to women treated with Topamax (topiramate) during pregnancy and placed it in Pregnancy Category D. Cognitive and word-finding difficulties, which may occur in some patients, may respond to piracetam. Carbonation dysgeusia (distortion of the sense of taste-sensation of carbonation) may respond to and/or be prevented with zinc. Topiramate has been associated with a statistically significant increase in suicidality, and "suicidal thoughts or actions" is now listed as one of the possible side effects of the drug "in a very small number of people, about 1 in 500."

== Isolation == The isolation of tryptophan was first reported by Frederick Hopkins in 1901. Hopkins recovered tryptophan from hydrolysed casein, recovering 4–8 g of tryptophan from 600 g of crude casein.

However, benzodiazepines have been used clinically to manage the adverse psychological effects of psychedelics, for instance in clinical studies and in the emergency department. A clinical trial of psilocybin and midazolam coadministration found that midazolam clouded the effects of psilocybin and impaired memory of the experience. Benzodiazepines might interfere with the therapeutic effects of psychedelics, such as sustained antidepressant effects. Some serotonergic psychedelics, for instance dimethyltryptamine (DMT) and 5-MeO-DMT, are highly susceptible substrates for monoamine oxidase (MAO), specifically MAO-A, and hence can be greatly potentiated by monoamine oxidase inhibitors (MAOIs). An example of this is ayahuasca, in which plants containing both DMT and harmala alkaloids acting as MAOIs such as harmine and harmaline are combined. This allows DMT to become orally active and to have a much longer duration of action than usual. The 2C psychedelics, such as 2C-B, 2C-I, and 2C-E, are also substrates of both MAO-A and MAO-B, and may likewise be greatly potentiated by MAOIs. Examples of MAOIs that may potentiate psychedelics behaving as MAO-A and/or MAO-B substrates include phenelzine, tranylcypromine, isocarboxazid, moclobemide, and selegiline. Combination of MAO-substrate psychedelics with MAOIs can result in overdose and serious toxicity, including death. Other psychedelics, such as LSD, are not substrates of MAO and are not potentiated by MAOIs.

Sources: en.wikipedia.org

Frequently asked questions

How is selank identified in a laboratory?

Identity is confirmed by matching the retention time in reversed-phase chromatography against a reference standard and by measuring the molecular mass with mass spectrometry. Tandem mass spectrometry or amino acid analysis can verify the sequence of the seven residues. Because the peptide contains no aromatic amino acids, detection at 280 nm is not useful.

How should selank powder be stored?

Lyophilized powder is normally stored desiccated at -20 °C, protected from light and moisture. Powder kept under these conditions is generally stable for long periods. Solutions are less stable and are usually prepared immediately before use.

Does a purity figure guarantee quality?

A purity value from one chromatographic method does not capture every possible impurity. Related peptides with similar retention behavior, counterions, and residual solvents may not appear in the same analysis. Independent testing with an orthogonal method provides stronger assurance of identity and content.

How should the powder be stored?

Dry powder is normally held at -20 degrees Celsius or below in a sealed, light-protected container with desiccant. Brief room-temperature handling during weighing is generally tolerated. Storage instructions vary between suppliers, so the accompanying certificate of analysis should be followed.

Network